Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Regenxbio Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Biological Products, (No Diagnostic Substances)
No intraday reading yet this session.
Regenxbio Inc. has 9 disclosed suppliers and 11 disclosed customers. Each one is named in an SEC filing, either Regenxbio Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of RGNX revenue | Skew |
|---|---|---|---|
| NVSNovartis Gene Therapies, Inc. (formerly AveXis, Inc.) (Novartis Gene Therapies) | 0.29% | 98.00% | 333× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“One customer (Novartis Gene Therapies) accounted for approximately 98%, 95% and 90% of our total revenues for the years ended December 31, 2024, 2023 and 2022, respectively.”
$167M relationship333× more of RGNX’s book than NVS’s
basisRGNX fy2025 · closed 2025-12 $170MNVS fy2025 · closed 2025-12 $56.7B
FILING10-K0000950170-25-038770cik 0001590877
“Clearside will be responsible for supplying the SCS Microinjector in support of our preclinical studies, clinical studies and commercial use.”
FILING10-K0000950170-25-038770cik 0001590877
“In August 2018, we entered into a license agreement with Emory University (Emory) for the exclusive rights to Emory's undivided interest in intellectual property that we and Emory jointly own relating to the delivery of AAV vectors to the CNS.”
FILING10-K0001193125-26-094013cik 0001590877
“In November 2014, we entered into a license agreement with Regents of the University of Minnesota (Minnesota) for the exclusive rights to Minnesota's undivided interest in intellectual property that Minnesota and we jointly own relating to the delivery of AAV vectors to the CNS.”
FILING10-K0001193125-26-094013cik 0001590877
“In February 2009, we entered into an exclusive, worldwide license agreement with Penn for patent and other intellectual property rights relating to a gene therapy technology platform based on AAVs discovered at Penn in the laboratory of James M. Wilson, M.D., Ph.D.”
FILING10-K0001193125-26-094013cik 0001590877
“Under the terms of our Collaboration and License Agreement with AbbVie (the AbbVie Collaboration and License Agreement), we received an upfront payment of $370 million.”
FILING10-K0000950170-25-038770cik 0001590877
“The use of AAV9 to deliver any sequence that affects the expression of the GRIK2 gene in humans has been exclusively licensed from Regenxbio Inc. ("Regenxbio").”
FILING10-K0001104659-26-021898cik 0001590560disclosed by QURE
“We recognized credit recoveries of $5.0 million during the year ended December 31, 2024 related to the full collection of amounts due under our settlement agreement with Abeona Therapeutics Inc. (Abeona), for which we had previously recorded an allowance for credit losses.”
FILING10-K0000950170-25-038770cik 0001590877
“Interest expense consists primarily of interest imputed on the liability related to the sale of future Zolgensma royalties to entities managed by Healthcare Royalty Management, LLC (collectively, HCR).”
FILING10-K0000950170-25-038770cik 0001590877
“In December 2020, we sold a portion of our royalty rights from the net sales of Zolgensma to entities managed by Healthcare Royalty Management, LLC (HCR) for a gross purchase price of $200 million.”
FILING10-K0000950170-25-038770cik 0001590877
“Under the terms of the Nippon Shinyaku Collaboration and License Agreement, we will receive an upfront payment of $110 million.”
FILING10-K0000950170-25-038770cik 0001590877
“In March 2009, we entered into a license agreement with GSK, which was amended in April 2009, in order to secure the exclusive rights to patents and patent applications covering NAV Technology that GSK had previously licensed from Penn (subject to certain rights retained by GSK and Penn).”
FILING10-K0001193125-26-094013cik 0001590877
“In September 2023, we entered into an ATM Equity Offering SM Sales Agreement with BofA Securities, Inc. (BofA) pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $150.0 million from time to time through BofA, acting as our sales agent (the BofA ATM Program).”
FILING10-K0000950170-25-038770cik 0001590877
“In June 2022, we entered into a license agreement with Johns Hopkins University (JHU) for the exclusive rights to JHU's undivided interest in intellectual property jointly owned by JHU and us relating to suprachoroidal delivery of anti-VEGF vectors.”
FILING10-K0000950170-25-038770cik 0001590877
“In December 2024, we entered into a Sales Agreement with Leerink Partners LLC (Leerink) pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $150.0 million from time to time through Leerink, acting as our sales agent (the Leerink ATM Program).”
FILING10-K0000950170-25-038770cik 0001590877
“The Company has a license agreement with REGENXBIO, Inc., or REGENX, for an exclusive, sublicensable, worldwide commercial license under certain intellectual property for preclinical and clinical research and development, and commercialization of drug therapies using REGENX's licensed patents for the treatment of OTC deficiency and GSD1a.”
FILING10-K0000950170-25-023312cik 0001515673disclosed by RARE
“We have also taken an active role in the formation of several of our NAV Technology Licensees, including being a founding shareholder in Dimension Therapeutics, Inc., Prevail Therapeutics Inc. and Corlieve Therapeutics SAS, all of which were acquired in strategic transactions since their formation.”
FILING10-K0000950170-25-038770cik 0001590877
“We have also taken an active role in the formation of several of our NAV Technology Licensees, including being a founding shareholder in Dimension Therapeutics, Inc., Prevail Therapeutics Inc. and Corlieve Therapeutics SAS, all of which were acquired in strategic transactions since their formation.”
FILING10-K0000950170-25-038770cik 0001590877
“We have also taken an active role in the formation of several of our NAV Technology Licensees, including being a founding shareholder in Dimension Therapeutics, Inc., Prevail Therapeutics Inc. and Corlieve Therapeutics SAS, all of which were acquired in strategic transactions since their formation.”
FILING10-K0000950170-25-038770cik 0001590877
“In May 2025, we entered into a loan agreement with entities managed by Healthcare Royalty Management, LLC (collectively and with other affiliated entities, HCR).”
FILING10-K0001193125-26-094013cik 0001590877
Watchlist prices, news filtered to it, and its next report on your desk.
RGNX (Regenxbio Inc.) has 9 disclosed suppliers and 11 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: RARE −3.71%, in healthcare.